BIOMEDICA LIFE SCIENCES SA Expanding a commercial SME specializing in radiopharmaceuticals and high-tech medical imaging instrumentation into a dynamic.

Slides:



Advertisements
Similar presentations
Patras RUnUP Thematic Network Closing Conference Dr. Ioannis Kostopoulos 12 May 2011.
Advertisements

EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.
2nd Panel, Best Practices: “ IPR in Successful University-Industry Collaborations” Dr. Tamar Raz, CEO Hadasit, the Technology Transfer Company of Hadassah.
Health Care Science Diagnostic Services. What is Diagnostic Services? Workers in this area help with the diagnosis of illness and diseases. They may or.
Inno|Praxis International Ltd.. Creating world innovation centres Skolkovo Summit of Innovation Economy Creators Mervi Käki.
The Israel Export & International Cooperation Institute Israel’s Medical Devices and Supplies Industry Rising to the Challenge.
Connecting the Technopark to the Incubator Association of University Research Parks, 2012 © Harold Strong, AURP Immediate Past President Director of Discovery.
Presenter Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference.
GENERAL SECRETARIAT FOR RESERCH AND TECHNOLOGY CREATION OF SPIN-OFF COMPANIES PROGRAM “PRAXE” VASSILIS KALERIDIS DIRECTORATE OF TECHNOLOGICAL DEVELOPMENT.
Biotechnology Incubators in Israel. The Israeli Biotechnology Market 160 companies (30% in therapeutics) 4000 employees Market valuation: $3.5 billion.
Strategic Plan - Draft June 23, Outline Mission/Vision/Goals of Alliance Summary: Strategic Plan Recommendations Part I: Institute of Health Science.
Centre for Health & Technology Maritta Perälä-Heape, PhD Director, CHT.
EU Funding: The European Research Council Nikki Muckle Strategy & Change – Research Strategy.
Partnerships & Alliances Molecular Diagnostics Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim.
The Alfred E. Mann Institute for Biomedical Engineering An Experiment in Technology Transfer Gerald E. Loeb, M.D. Director of the Medical Device Development.
Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy
European Technology Platform – Innovative Medicines for Europe 1 st Workshop on Education and Training, 24 & 25 February 2005 Educational gaps in the R&D.
This venture represents the culmination point of over 10 years of participation as a NORD Corporate Council member.
1 Life Technologies™ Proprietary | AIPLA Winter Meeting Presentation January 2013.
Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.
Proposal for a European Faculty of Regenerative Medicine ScanBalt Campus Knowledge centers.
Kick-off University Partners Meeting September 18, 2012 Michael Owen, VP Research, Innovation & International, UOIT on behalf of Consortium partners Southern.
National Center for Scientific Research “Demokritos” 50 years of Excellence in Science.
Centre for Knowledge Transfer & Development University of Crete June, 2010 Antonios Aggelakis
Finding a way or making one. Labor’s headquarter is in Rome Labor.
Deutsche Gesellschaft für Technische Zusammenarbeit (GTZ) GmbH German – Macedonian technical cooperation GTZ Project for Technology Transfer PAXIS European.
Presidency of Council of Ministers National Committee for Biosafety, Biotechnology and Life Sciences (D.P.C.M. March 19, 2007)
NEW INNOVATION SUPPORT SERVICES, case Finland Mervi Käki, CEO, Partner
Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry.
Director, DG RTD, Directorate International Cooperation
CLUNET pilot project High Technology Products Manufacturers' Cluster A pilot project proposed by as part of the european project Marko Jurančič; Ljubljana;
Panagiotis KARNIOURAS NCP for SPACE / Technology Transfer Consultant PRAXI/ HELP-FORWARD Network … the Greek experience 9 October 2009.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Recognition Of Team Science Faculty Appointments, Promotions and Titles at The Geisel School of Medicine at Dartmouth “Recognition by peers as an investigator.
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Technology Transfer Center of the University of Lodz High-Tech Accelerator - Innovation Center Foundation of the University of Lodz Bridging science and.
Research and Innovation Research and Innovation Research and Innovation Research and Innovation How can networking in Science and Technology help SMEs.
© Fraunhofer MOEZ Mathias Rauch, Deputy Director Fraunhofer Center for Central and Eastern Europe MOEZ Commercialization of Technologies in Germany: Fraunhofer.
OPEN DAYS 2008 Brussels, 07 October 2008 Effective Regional Strategies and Policies for open innovation.
General Secretariat for Research & Technology (GSRT) Ministry of Development Dr. Dimitris DENIOZOS Secretary General for Research and Technology Thessaloniki,
Partners in Aquatic Biotechnology Overview The ATC is an EU-supported initiative It aims to make more accessible to the commercial sector, the skills.
RESIDENT PROJECTS ROBERT LEONHARD QUALITY IMPROVEMENT MANAGER.
R&D IN HUNGARY National Research and Technological Innovation Fund Independent central government office responsible for R&D Expected new budget: approx.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Science and Technology Development Fund: Supporting Research and Technology Development Eng. Mohamed Nagaty Innovation Manager November 22 nd, 2010.
Susan R. Kayar, PhD Health Scientist Administrator Research Infrastructure NCRR, NIH Funding Opportunities through the National Center for Research Resources.
EU Seventh Framework Programme - FP7. FP7 overview The Seventh Framework Programme (FP7) is EU’s main instrument for funding research in Europe FP7 will.
1 Direction scientifique Networks of Excellence objectives  Reinforce or strengthen scientific and technological excellence on a given research topic.
National Plans for Rare Diseases: Bulgarian experience ICORD meeting – February 2009, Roma, Italy Rumen Stefanov.
Consortium for Interdisciplinary Studies on Science for Aging.
Knowledge Exchange. Ideas Uncorked. June 3, 2013.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Horizon 2020 Opportunities for SMEs European Commission Enterprise and Industry.
Policy on the Management of Intellectual Property in Technology Transfer Activities at CERN CERN/FC/5434/RA Technology Transfer Network Meeting – 10 th.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
Concerted Efforts: The Establishments of Thematic Centers of Excellence Mamoun Muhammed Royal Institute of Technology (KTH) SE Stockholm, Sweden.
BEST PRACTICES FROM GIJÓN TO SUPPORT INNOVATION AND MOVE TOWARDS ECONOMIC RECOVERY Tallin, 8th October 2009 Laura González Méndez Local Agency of Economic.
Personalised Healthcare FP7 Challenge 5: ICT for Health, Aging Well, Inclusion and Governance.
1 Extending the Wisconsin Idea UW Funding Opportunities for Technologies with Promising Potential.
GREECE: Meeting of the National Councils for S&T policy of the EU Member Countries Prague,25-26 May 2006 National Research Council General Secretariat.
NSW Government Agencies Supporting Clinical Trials Strategic Planning, Policy Advice & Funding for Medical Research Economic Development & Support for.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
EUROPEAN HUB EU Funds for SMEs and Startups Innovation and Investment.
«Innovation & Entrepreneurship at Patras Science Park»
Recent Evolution of New Drug Review and Approval System in Korea
The Essentia Institute of Rural Health (EIRH) is
The introduction of NGS panel tests in the Belgian healthcare system
An Introduction to the NIHR programmes
Molecular Diagnostics - Europe Market to Hit $3.3 Bn by 2024 : Graphical Research According to the Graphical Research new growth forecast report titled.
Presentation transcript:

BIOMEDICA LIFE SCIENCES SA Expanding a commercial SME specializing in radiopharmaceuticals and high-tech medical imaging instrumentation into a dynamic group of Biotechnology companies

BIOMEDICA LIFE SCIENCES SA BIOMEDICA LIFE SCIENCES SA Established in 1994 Total number of employees: revenue from sales 4,016 mil €EBT 0,9 mil € Coupling BIOMEDICA’s management and marketing resources and expertise with excellence in biotechnological research of Greek Research Institutes and University Laboratories Main concept for the expansion:

Strategy Main Points and Objectives 1. Establishing the company’s R&D base through the collaboration with research groups in National Research Centres and Universities 2. Organizing and managing a state-of-the-art Radiopharmaceuticals Production Unit (GMP) based on the infrastructure and know-how of NCSR “Demokritos” 3. Designing, conducting and funding of multicenter clinical trials in Greece and abroad 4. Expanding into Molecular Diagnostics & Genetic Testing

1.Establishing the R&D Base 1.Establishing the R&D Base Collaborating with the Greek Research Community I. Direct funding of novel research ideas in Radiopharmacy and Radiodiagnostics 1. Radiolabeled Biomolecules in Diagnosis and Therapy Tc 99m labelled bombesin, minigastrin and neurotensin analogues Principal Investigators: A. Varvarigou, NCSR “Demokritos” T. Maina, B. Nock, NCSR “Demokritos” Greek patents granted – European patents pending Tc 99m labelled YIGSR for radiodiagnosis & immunotherapy Principal Investigator:G. Koliakos, University of Thessalonica Greek patent granted – European patent granted 2. Peptide Design and Synthesis Principal Investigator: P. Cordopatis, University of Patras Greek patents granted – European patents pending

II. Participating as co-sponsor and/or end-user in selected research programs funded by GSRT and EU EKBAN «Τεχνητά Χρωμοσώματα Εντομοιών (ΤΕΧΠΕΝ) και Τεχνολογίες για Γονιδιακή Θεραπεία και Συνεχή Υψηλού Επιπέδου Έκφραση Θεραπευτικών Πρωτεϊνών σε εντομικά Συστήματα Παραγωγής», ΕΚΕΦΕ «Δημόκριτος», Ινστιτούτο Pasteur, Biomedica, € (budget of project, Biomedica participation € ) ΗΡΩΝ «Ανάπτυξη και αξιολόγηση ραδιοεπισημασμένων βιομορίων για διάγνωση ή/και θεραπεία νεοπλασιών διαφόρων μορφών» Biomedica, € (granted by 50%) ΠΕΝΕΔ – ΔΙΑΚΡΑΤΙΚΕΣ ΣΥΝΕΡΓΑΣΙΕΣ

Biomedica Research Personnel May 2004 BIOMEDICA Funded Research Programs: 7 full time positions – 4 PhDs Co-Sponsored Research Programs: 5 full time positions – 4 PhDs

2. Organizing and Managing a Radiopharmaceutical Production Unit A strategic alliance between BIOMEDICA and the Institute of Radioisotopes & Radiodiagnostic Products has been approved by the Board of Directors of NCSR “Demokritos” in May 2004

Joint Venture  Organization and Management of the Institute’s unique Infrastructure  Implementation of Good Manufacturing Practice (GMP) Protocols

 Production of selected highly demanded radiopharmaceuticals in Greece and abroad  Pilot production of novel products for clinical trials  Providing specialized GMP lyophilization services to third parties  Providing education and training

NCSR “Demokritos” Infrastructure  Class 100 lyophilization clean room  Radiochemical – Radiobiological Quality Control Labs  Hot-Cells A joint BIOMEDICA & NCSR “Demokritos” team will carry out development, production and QC of radiopharmaceuticals A joint BIOMEDICA & NCSR “Demokritos” team will carry out development, production and QC of radiopharmaceuticals

4. Expanding into Molecular Diagnostics & Genetic Testing BioGenomica S.A BioGenomica S.A. Centre for Genetic Testing and Analyses A spin-off Company of NCSR “Demokritos” established in February 2004 The company’s business plan has been successfully incorporated in the PRAXE Phase B Program of GSRT with a total budget of 2 mil €.

BioGenomica SA BioGenomica SA Centre for Genetic Testing and Analyses a spin-off company of NCSR “Demokritos” Genetic testing for predisposition to hereditary diseases Cancer -Neurological and Psychiatric Disorders - Rare Diseases DNA sequencing tailoring specific laboratory needs Food industry – Public health

 Providing services to hospitals, clinics and diagnostic centres in Greece and abroad  Participation in international genetic testing networks  Providing services to the food and agricultural industry

June 2004: total number of employees: 6 (3 PhDs) State-of-the-art instrumentation: Automated DNA Sequencing, dHPLC, Real-time PCR and DNA microarray-based technologies  European Molecular Quality Network evaluation and accreditation

BioGenomica Research Establishment of International Scientific Advisory Board Design of clinical research protocols jointly with medical centers and collaborative groups and networks Participation in large-scale genetic epidemiology studies Incubation of basic science, biochemical and biophysical research projects jointly with Universities and Research Institutes